Top

PharmacoEconomics

Published in:

01-04-2015 | Systematic Review

Cost-of-Illness Studies for Bipolar Disorder: Systematic Review of International Studies

Authors: Huajie Jin, Paul McCrone

Published in: PharmacoEconomics | Issue 4/2015

Abstract

Background and Objectives

Bipolar disorder (BD) may result in a greater burden than all forms of cancer, Alzheimer’s disease and epilepsy. Cost-of-illness (COI) studies provide useful information on the economic burden that BD imposes on a society. Furthermore, COI studies are pivotal sources of evidence used in economic evaluations. This study aims to give a general overview of COI studies for BD and to discuss methodological issues that might potentially influence results. This study also aims to provide recommendations to improve practice in this area, based on the review.

Methods

A search was performed to identify COI studies of BD. The following electronic databases were searched: MEDLINE, EMBASE, PsycInfo, Cochrane Database of Systematic Reviews, HMIC and openSIGLE. The primary outcome of this review was the annual cost per BD patient. A narrative assessment of key methodological issues was also included. Based on these findings, recommendations for good practice were drafted.

Results

Fifty-four studies were included in this review. Because of the widespread methodological heterogeneity among included studies, no attempt has been made to pool results of different studies. Potential areas for methodological improvement were identified. These were: description of the disease and population, the approach to deal with comorbidities, reporting the rationale and impact for choosing different cost perspectives, and ways in which uncertainty is addressed.

Conclusions

This review showed that numerous COI studies have been conducted for BD since 1995. However, these studies employed varying methods, which limit the comparability of findings. The recommendations provided by this review can be used by those conducting COI studies and those critiquing them, to increase the credibility and reporting of study results.

Available only for authorised users

Anderson IM, Haddad PM, Scott J. Bipolar disorder. BMJ. 2012;345:e8508. doi:10.1136/bmj.e8508.

Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psych. 2011;68(3):241–51. doi:10.1001/archgenpsychiatry.2011.12.

Guilbert JJ. The world health report 2002: reducing risks, promoting healthy life. Educ Health. 2003;16(2):230.CrossRef

Hirschfeld RMA, Vornik LA. Bipolar disorder: costs and comorbidity. Am J Manage Care. 2005;11(Suppl 3):S85–90.

Krishnan KRR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005;67(1):1–8.PubMedCrossRef

McCrone P, Knapp M, King’s F, Patel A, Dhanasiri S. Paying the price: the cost of mental health care in England to 2026. King’s Fund. 2008;143:69–79.

Woods SW. The economic burden of bipolar disease. J Clin Psychiatry. 2000;1(Suppl 13):38–41.

Lum TY, Parashuram S, Shippee TP, Wysocki A, Shippee ND, Homyak P, et al. Diagnosed prevalence and health care expenditures of mental health disorders among dual eligible older people. Gerontologist. 2013;53(2):334–44. doi:10.1093/geront/gns163.

Parker G, McCraw S, Hadzi-Pavlovic D, Fletcher K. Costs of the principal mood disorders: a study of comparative direct and indirect costs incurred by those with bipolar I, bipolar II and unipolar disorders. J Affect Disord. 2013;149(1–3):46–55. doi:10.1016/j.jad.2012.10.002.

10.

Begley CE, Annegers JF, Swann AC, Lewis C, Coan S, Schnapp WB, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics. 2001;9(5 Pt I):483–95.CrossRef

11.

Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord. 2002;4(6):398–405. doi:10.1034/j.1399-5618.2002.01148.x.

12.

Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry. 2002;180:227–33.PubMedCrossRef

13.

Rice DP. Cost of illness studies: what is good about them? J Int Soc Child Adolesc Injury Prev. 2000;6(3):177–9.CrossRef

14.

Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29(8):653–71. doi:10.2165/11588380-000000000-00000.

15.

Costa N, Derumeaux H, Rapp T, Garnault V, Ferlicoq L, Gillette S, et al. Methodological considerations in cost of illness studies on Alzheimer disease. Health Econ Rev. 2012;1:1–12.

16.

Segel JE. Cost-of-illness studies: a primer. USA: RTI-UNC Center of Excellence in Health Promotion Economics RTI international; 2006. p. 1–39.

17.

Kriza C, Emmert M, Wahlster P, Niederlander C, Kolominsky-Rabas P. Cost of illness in colorectal cancer: an international review. Pharmacoeconomics. 2013;31(7):577–88. doi:10.1007/s40273-013-0055-4.

18.

Ian S, Marcello M, James T. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6(1):51–9.CrossRef

19.

Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718–79. doi:10.1016/j.euroneuro.2011.08.008.

20.

Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–79. doi:10.1016/j.euroneuro.2011.07.018.

21.

Fajutrao L, Locklear J, Priaulx J, Heyes A. A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin Pract Epidemiol Ment Health. 2009;5:3. doi:10.1186/1745-0179-5-3.

22.

Patel A. The cost of mood disorders. Psychiatry. 2009;8(2):76–80. doi:10.1016/j.mppsy.2008.10.021.

23.

Pini S, de Queiroz V, Pagnin D, Pezawas L, Angst J, Cassano GB, et al. Prevalence and burden of bipolar disorders in European countries. Eur Neuropsychopharmacol. 2005;15(4):425–34.PubMedCrossRef

24.

Andlin-Sobocki P, Wittchen H. Cost of affective disorders in Europe. Eur J Neurol. 2005;12(s1):34–8. doi:10.1111/j.1468-1331.2005.01195.x.

25.

Bauer M, Unutzer J, Pincus HA, Lawson WB. Bipolar disorder. Ment Health Serv Res. 2002;4(4):225–9. doi:10.1023/A:1020968616616.

26.

Kleinman L, Lowin A, Flood E, Gandhi G, Edgell E, Revicki D. Costs of bipolar disorder. Pharmacoeconomics. 2003;21(9):601–22.PubMedCrossRef

27.

Post RM. The impact of bipolar depression. J Clin Psychiatry. 2005;66(Suppl 5):5–10.PubMed

28.

Stimmel GL. Economic grand rounds: the economic burden of bipolar disorder. Psychiatric Serv. 2004;55(2):117–8.CrossRef

29.

Fagiolini A, Forgione R, Maccari M, Cuomo A, Morana B, Dell’Osso MC, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord. 2013;148(2–3):161–9. doi:10.1016/j.jad.2013.02.001.

30.

Fagiolini A, Chengappa KNR, Soreca I, Chang J. Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs. 2008;22(8):655–69. doi:10.2165/00023210-200822080-00004.

31.

Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in bipolar disorder. Curr Med Res Opin. 2004;20(2):139–54. doi:10.1185/030079903125002801.

32.

Montejano LB, Goetzel RZ, Ozminkowski RJ. Impact of bipolar disorder on employers: rationale for workplace interventions. Dis Manage Health Outcomes. 2005;13(4):267–80. doi:10.2165/00115677-200513040-00005.

33.

Lothgren M. Economic evidence in affective disorders: a review. Eur J Health Econom. 2004;5(Suppl 1):S12–S20. doi:10.1007/s10198-005-0283-4.

34.

Manning JS. Burden of illness in bipolar depression. Prim Care Comp J Clin Psychiatry. 2006;7(6):259–67.CrossRef

35.

Sajatovic M. Bipolar disorder: disease burden. Am J Manage Care. 2005;11(Suppl 3):S80–4.

36.

Keck PE Jr, Kessler RC, Ross R. Clinical and economic effects of unrecognized or inadequately treated bipolar disorder. J Psychiatr Pract. 2008;14(Suppl 2):31–8.PubMedCrossRef

37.

Patel A. The cost of mood disorders. Psychiatry. 2006;5(4):141–5. doi:10.1383/psyt.2006.5.4.141.

38.

Simon GE. Social and economic burden of mood disorders. Biol Psychiatry. 2003;54(3):208–15. doi:10.1016/S0006-3223%2803%2900420-7.

39.

Roijen L, Hoeijenbos M, Regeer E, ten Have M, Nolen W, Veraart C, et al. The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands. Acta Psychiatrica Scandinavica. 2004;110(5):383–92. doi:10.1111/j.1600-0447.2004.00403.x.

40.

Guo JJ, Keck Jr PE, Li H, Jang R, Kelton CML. Treatment costs and health care utilization for patients with bipolar disorder in a large managed care population. Value Health. 2008;11(3):416–23. doi:10.1111/j.1524-4733.2007.00287.x.

41.

Dusetzina SB, Farley JF, Weinberger M, Gaynes BN, Sleath B, Hansen RA. Treatment use and costs among privately insured youths with diagnoses of bipolar disorder. Psychiatr Serv. 2012;63(10):1019–25. doi:10.1176/appi.ps.201100516.

42.

Peele PB, Axelson DA, Xu Y, Malley EE. Use of medical and behavioral health services by adolescents with bipolar disorder. Psychiatr Serv. 2004;55(12):1392–6. doi:10.1176/appi.ps.55.12.1392.

43.

Berry EA, Heaton PC, Kelton CML. National estimates of the inpatient burden of pediatric bipolar disorder in the United States. J Ment Health Policy Econom. 2011;14(3):115–23.

44.

Gilmer T, Ojeda VD, Folsom D, Fuentes D, Criado V, Garcia P, et al. Costs of community-based public mental health services for older adults: variations related to age and diagnosis. Int J Geriatr Psychiatry. 2006;21(12):1121–6. doi:10.1002/gps.1616.

45.

Rajagopalan K, Kleinman NL, Brook RA, Gardner HH, Brizee TJ, Smeeding JE. Costs of physical and mental comorbidities among employees: a comparison of those with and without bipolar disorder. Curr Med Res Opin. 2006;22(3):443–52.PubMedCrossRef

46.

Hong J, Reed C, Novick D, Haro JM, Aguado J. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: Results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Study. Psychiatr Res. 2011;190(1):10–14. doi:10.1016/j.psychres.2011.04.016.CrossRef

47.

Hong J, Reed C, Novick D, Haro JM, Windmeijer F, Knapp M. The cost of relapse for patients with a manicmixed episode of bipolar disorder in the emblem study. Pharmacoeconomics. 2010;28(7):555–66. doi:10.2165/11535200-000000000-00000.

48.

De Zelicourt M, Dardennes R, Verdoux H, Gandhi G, Khoshnood B, Chomette E, et al. Frequency of hospitalisations and inpatient care costs of manic episodes: in patients with bipolar I disorder in France. Pharmacoeconomics. 2003;21(15):1081–90. doi:10.2165/00019053-200321150-00002.

49.

Olie JP, Levy E. Manic episodes: the direct cost of a three-month period following hospitalisation. Eur Psychiatry. 2002;17(5):278–86.PubMedCrossRef

50.

Tafalla M, Salvador-Carulla L, Saiz-Ruiz J, Diez T, Cordero L. Pattern of healthcare resource utilization and direct costs associated with manic episodes in Spain. BMC Psychiatry.2010;10:31. doi:10.1186/1471-244X-10-31.

51.

Stender M, Bryant-Comstock L, Phillips S. Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis. Clin Ther. 2002;24(10):1668–76.PubMedCrossRef

52.

Harley C, Li H, Corey-Lisle P, L’Italien GJ, Carson W. Influence of medication choice and comorbid diabetes: the cost of bipolar disorder in a privately insured US population. Soc Psychiatr Psychiatr Epidemiol. 2007;42(9):690–7. doi:10.1007/s00127-007-0222-z.

53.

Ohsfeldt RL, Lage MJ, Rajagopalan K. Medication use, service utilization, and medical costs associated with new episodes of bipolar disorder: evidence from a retrospective claims database. Prim Care Comp J Clin Psychiatry. 2007;9(4):280–6.CrossRef

54.

Tang C, Hsieh MH, Hung S, Lee IH, Lin Y, Yang YK. One-year post-hospital medical costs and relapse rates of bipolar disorder patients in Taiwan: a population-based study. Bipolar Disord. 2010;12(8):859–65. doi:10.1111/j.1399-5618.2010.00878.x.

55.

Ekman M, Granstrom O, Omerov S, Jacob J, Landen M. Societal costs of bipolar disorder: the case of Sweden. Value in Health. ISPOR 13th Annual European Congress Prague Czech Republic, Start: 20101106 Conference End: 20101109.

56.

Li J, McCombs JS, Stimmel GL. Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. J Affect Disord. 2002;71(1–3):131–9.PubMedCrossRef

57.

Stensland MD, Schultz JF, Frytak JR. Diagnosis of unipolar depression following initial identification of bipolar disorder: a common and costly misdiagnosis. J Clin Psychiatry. 2008;69(5):749–58. doi:10.4088/JCP.v69n0508.

58.

Runge C, Grunze H. Annual costs of bipolar disorders in Germany [German]. Nervenarzt. 2004;75(9):896–903. doi:10.1007/s00115-004-1691-x.

59.

Stang PE, Frank C, Kalsekar A, Yood MU, Wells K, Burch S. The clinical history and costs associated with delayed diagnosis of bipolar disorder. MedGenMed Medscape Gen Med. 2006;8(2):18.

60.

Bagalman E, Muser E, Choi JC, Durden E, Macfadden W, Haskins JT, et al. Health care resource utilization and costs in a commercially insured population of patients with bipolar disorder type I and frequent psychiatric interventions [Erratum appears in Clin Ther. 2011 Dec;33(12):2093]. Clin Ther. 2011;33(10):1381–90.e4. doi:10.1016/j.clinthera.2011.09.005.

61.

Durden E, Bagalman E, Muser E, Choi JC, Crivera C, Dirani R, et al. Characteristics, healthcare utilization and costs of bipolar disorder type i patients with and without frequent psychiatric intervention in a Medicaid population. J Med Econom. 2010;13(4):698–704. doi:10.3111/13696998.2010.531828.

62.

Guo JJ, Keck PE, Li H, Patel NC. Treatment costs related to bipolar disorder and comorbid conditions among medicaid patients with bipolar disorder. Psychiatr Serv. 2007;58(8):1073–8. doi:10.1176/appi.ps.58.8.1073.

63.

Gianfrancesco FD, Sajatovic M, Rajagopalan K, Wang RH. Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder. Clin Ther. 2008;30(7):1358–74. doi:10.1016/S0149-2918%2808%2980062-8.

64.

Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52(6):805–11. doi:10.1176/appi.ps.52.6.805.

65.

Williams MD, Shah ND, Wagie AE, Wood DL, Frye MA. Direct costs of bipolar disorder versus other chronic conditions: an employer-based health plan analysis. Psychiatr Serv. 2011;62(9):1073–8. doi:10.1176/appi.ps.62.9.1073.

66.

Centorrino F, Mark TL, Talamo A, Oh K, Chang J. Health and economic burden of metabolic comorbidity among individuals with bipolar disorder. J Clin Psychopharmacol. 2009;29(6):595–600. doi:10.1097/JCP.0b013e3181bef8a6.

67.

Knoth RL, Chen K, Tafesse E. Datapoints: costs associated with the treatment of patients with bipolar disorder in a managed care organization. Psychiatric Serv (Washington, DC). 2004;55(12):1353.CrossRef

68.

Osby U, Tiainen A, Backlund L, Edman G, Adler M, Hallgren J, et al. Psychiatric admissions and hospitalization costs in bipolar disorder in Sweden. J Affect Disord. 2009;115(3):315–22. doi:10.1016/j.jad.2008.09.011.

69.

Rice DP, Miller LS. The economic burden of affective disorders. Br J Psychiatry. 1995;(27):34–42.

70.

Economics Access. Bipolar disorder: costs An analysis of the burden of bipolar disorder and related suicide in Australia. Canberra: Report for SANE Australia; 2002.

71.

Busch AB, Yoon F, Barry CL, Azzone V, Normand SLT, Goldman HH, et al. The effects of mental health parity on spending and utilization for bipolar, major depression, and adjustment disorders. Am J Psychiatry. 2013;170(2):80–87. doi:10.1176/appi.ajp.2012.12030392.

72.

Hsieh MH, Tang CH, Lee IH, Lai TJ, Lin YJ, Yang YK. Medical costs and vasculometabolic comorbidities among patients with bipolar disorder in Taiwan: a population-based and matched-control study. J Affect Disord. 2012;141(2–3):449–56. doi:10.1016/j.jad.2012.02.038.

73.

Gonzalez-Pinto A, Dardennes R, de Zelicourt M, Lopez P, Oliveros R, Vieta E, et al. In-patient care costs of patients with bipolar 1 disorder: a comparison between two European centers. J Affect Disord. 2010;121(1–2):152–5. doi:10.1016/j.jad.2009.05.010.

74.

Gardner HH, Kleinman NL, Brook RA, Rajagopalan K, Brizee TJ, Smeeding JE. The economic impact of bipolar disorder in an employed population from an employer perspective. J Clin Psychiatry. 2006;67(8):1209–18.PubMedCrossRef

75.

Wyatt R, Henter I. An economic evaluation of manic-depressive illness-1991. Social Psychiatry Psychiatric Epidemiol. 1995;30(5):213–9.

76.

Dilsaver SC. An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. J Affect Disord. 2011;129(1–3):79–83. doi:10.1016/j.jad.2010.08.030.

77.

Young AH, Rigney U, Shaw S, Emmas C, Thompson JM. Annual cost of managing bipolar disorder to the UK healthcare system. J Affect Disord. 2011;133(3):450–6. doi:10.1016/j.jad.2011.06.016.

78.

Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol. 2005;12(Suppl 1):1–27.PubMedCrossRef

79.

Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–51. doi:10.1001/archgenpsychiatry.2011.12.

80.

Ward MM, Javitz HS, Smith WM, Bakst A. A comparison of three approaches for attributing hospitalizations to specific diseases in cost analyses. Int J Technol Assess Health Care. 2000;16(1):125–36.PubMedCrossRef

81.

Hirschfeld RMA, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 Survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161–74.PubMedCrossRef

82.

Dittmann S, Biedermann NC, Grunze H, Hummel B, Scharer LO, Kleindienst N, et al. The Stanley Foundation Bipolar Network: results of the naturalistic follow-up study after 2.5 years of follow-up in the German centres. Neuropsychobiology. 2002;46(Suppl 1):2–9.PubMedCrossRef

83.

Pini S, de Queiroz V, Pagnin D, Pezawas L, Angst J, Cassano GB et al. Prevalence and burden of bipolar disorders in European countries. Europ Neuropsychopharmacol. 2005;15(4):425–34.

84.

Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 2001;61(2):195–206.PubMedCrossRef

85.

Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982;60(3):429–62.PubMedCrossRef

86.

Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ. 2000;320(7245):1335.PubMedCentralPubMedCrossRef

87.

Sanderson K, Andrews G, Corry J, Lapsley H. Reducing the burden of affective disorders: is evidence-based health care affordable? J Affect Disord. 2003;77(2):109–25.PubMedCrossRef

88.

Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatr. 2004;184:526–33.CrossRef

89.

NCCMH. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Leicester and London: The British Psychological Society and the Royal College of Psychiatrists [Full guideline]. 2006.

90.

Berrios GE. The psychopathology of affectivity: conceptual and historical aspects. Psychol Med. 1985;15(4):745–58.PubMedCrossRef

91.

World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992.

92.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (4th edn). Washington DC: APA; 1994.

93.

Norlund A, Apelqvist J, Bitzen PO, Nyberg P, Schersten B. Cost of illness of adult diabetes mellitus underestimated if comorbidity is not considered. J Intern Med. 2001;250(1):57–65.PubMedCrossRef

94.

Pagano E, Brunetti M, Tediosi F, Garattini L. Costs of diabetes. A methodological analysis of the literature. Pharmacoeconomics. 1999;15(6):583–95.PubMedCrossRef

95.

Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics. 1992;2(1):1–4PubMedCrossRef

96.

Honeycutt A et al. Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment–United States, 2003. Morb Mortal Weekly Rep. 2004;53(3):57–9.

97.

Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14(2):171–89.PubMedCrossRef

98.

Ament A, Evers S. Cost of illness studies in health care: a comparison of two cases. Health Policy. 1993;26(1):29–42.PubMedCrossRef

99.

Goeree R, O’Brien BJ, Blackhouse G, Agro K, Goering P. The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia. Canadian Psychiatr - Revue Canadienne de Psychiatrie. 1999;44(5):455–63.

100.

Stensland MD, Jacobson JG, Nyhuis A. Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care. J Affect Disord. 2007;101(1–3):187–93.PubMedCrossRef

101.

Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the “top 10” physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med. 2003;45(1)5–14. doi:10.1097/00043764-200301000-00007.PubMedCrossRef

102.

Peele PB, Xu Y, Kupfer DJ. Insurance expenditures on bipolar disorder: clinical and parity implications. Am psychiatr. 2003;160(7):1286–90.CrossRef

103.

Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv. 1999;50(10):1303–8.PubMedCrossRef

104.

Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155–62. doi:10.1111/j.1468-1331.2011.03590.x.PubMedCrossRef

Title: Cost-of-Illness Studies for Bipolar Disorder: Systematic Review of International Studies
Authors: Huajie Jin
Paul McCrone
Publication date: 01-04-2015
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 4/2015
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-014-0250-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cost-of-Illness Studies for Bipolar Disorder: Systematic Review of International Studies

Abstract

Background and Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2015

Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis

An Educational Review of the Statistical Issues in Analysing Utility Data for Cost-Utility Analysis

Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control

Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada

Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilization-Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy

Economic Features of Antibiotic Resistance: The Case of Methicillin-Resistant Staphylococcus aureus